Patents by Inventor Brian C. Cunningham

Brian C. Cunningham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5955340
    Abstract: Novel carbonyl hydrolase mutants derived from the amino acid sequence of naturally-occurring or recombinant non-human carbonyl hydrolases and DNA sequences encoding the same. The mutant carbonyl hydrolases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant carbonyl hydrolase to encode the substitution, insertion or deletion of one or more amino acids in the amino acid sequence of a precursor carbonyl hydrolase. Such mutants have one or more properties which are different than the same property of the precursor hydrolase.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 21, 1999
    Assignee: Genencor International, Inc.
    Inventors: Richard Ray Bott, Robert Mark Caldwell, Brian C. Cunningham, David Aaron Estell, Scott Douglas Power, James Allen Wells
  • Patent number: 5854026
    Abstract: A human growth hormone variant including the set of amino acid substitutions H18A, Q22A, F25A, D26A, Q29A, E65A, K168A, E174A is disclosed. Also disclosed is a nucleic acid encoding this variant, along with a vector including the nucleic acid, a host cell including the vector, and a process for preparing the variant. The variant has enhanced affinity for human growth hormone receptor at site 1.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 29, 1998
    Assignee: Genentech, Inc.
    Inventors: Brian C. Cunningham, James A. Wells
  • Patent number: 5849535
    Abstract: Human growth hormone variants, DNA encoding the variants, vectors, host cells, pegylated forms of the variants, as well as methods of making the variants are disclosed.
    Type: Grant
    Filed: September 20, 1996
    Date of Patent: December 15, 1998
    Assignee: Genentech, Inc.
    Inventors: Brian C. Cunningham, Henry B. Lowman, James A. Wells, Ross G. Clark, Kenneth Olson, Germaine G. Fuh
  • Patent number: 5846932
    Abstract: Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 8, 1998
    Assignee: Genentech, Inc.
    Inventors: David G. Lowe, Brian C. Cunningham, David Oare, Robert S. McDowell, John P. Burnier
  • Patent number: 5834250
    Abstract: The invention provides methods for the systematic analysis of the structure and function of polypeptides by identifying active domains which influence the activity of the polypeptide with a target substance. Such active domains are determined by substituting selected amino acid segments of the polypeptide with an analogous polypeptide segment from an analog to the polypeptide. The analog has a different activity with the target substance as compared to the parent polypeptide. The activities of the segment-substituted polypeptides are compared to the same activity for the parent polypeptide for the target. A comparison of such activities provides an indication of the location of the active domain in the parent polypeptide. The invention also provides methods for identifying the active amino acid residues within the active domain of the parent polypeptide.
    Type: Grant
    Filed: June 30, 1997
    Date of Patent: November 10, 1998
    Assignee: Genentech, Inc.
    Inventors: James A. Wells, Brian C. Cunningham
  • Patent number: 5801038
    Abstract: Novel carbonyl hydrolase mutants derived from the amino acid sequence of naturally-occurring or recombinant non-human carbonyl hydrolases and DNA sequences encoding the same. The mutant carbonyl hydrolases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant carbonyl hydrolase to encode the substitution, insertion or deletion of one or more amino acids in the amino acid sequence of a precursor carbonyl hydrolase. Such mutants have one or more properties which are different than the same property of the precursor hydrolase.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 1, 1998
    Assignee: Genencor International Inc.
    Inventors: Richard Ray Bott, Robert Mark Caldwell, Brian C. Cunningham, David Aaron Estell, Scott Douglas Power, James Allen Wells
  • Patent number: 5766854
    Abstract: The invention provides methods for the systematic analysis of the structure and function of polypeptides by identifying active domains which influence the activity of the polypeptide with a target substance. Such active domains are determined by substituting selected amino acid segments of the polypeptide with an analogous polypeptide segment from an analog to the polypeptide. The analog has a different activity with the target substance as compared to the parent polypeptide. The activities of the segment-substituted polypeptides are compared to the same activity for the parent polypeptide for the target. A comparison of such activities provides an indication of the location of the active domain in the parent polypeptide. The invention also provides methods for identifying the active amino acid residues within the active domain of the parent polypeptide.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 16, 1998
    Assignee: Genentech, Inc.
    Inventors: James A. Wells, Brian C. Cunningham
  • Patent number: 5763257
    Abstract: Novel carbonyl hydrolase mutants derived from the amino acid sequence of naturally-occurring or recombinant non-human carbonyl hydrolases and DNA sequences encoding the same. The mutant carbonyl hydrolases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant carbonyl hydrolase to encode the substitution, insertion or deletion of one or more amino acids in the amino acid sequence of a precursor carbonyl hydrolase. Such mutants have one or more properties which are different than the same property of the precursor hydrolase.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 9, 1998
    Assignee: Genencor International, Inc.
    Inventors: Richard Ray Bott, Robert Mark Caldwell, Brian C. Cunningham, David Aaron Estell, Scott Douglas Power, James Allen Wells
  • Patent number: 5700676
    Abstract: Novel carbonyl hydrolase mutants derived from the amino acid sequence of naturally-occurring or recombinant non-human carbonyl hydrolases and DNA sequences encoding the same. The mutant carbonyl hydrolases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant carbonyl hydrolase to encode the substitution, insertion or deletion of one or more amino acids in the amino acid sequence of a precursor carbonyl hydrolase. Such mutants have one or more properties which are different than the same property of the precursor hydrolase.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 23, 1997
    Assignee: Genencor International Inc.
    Inventors: Richard Ray Bott, Robert Mark Caldwell, Brian C. Cunningham, David Aaron Estell, Scott Douglas Power, James Allen Wells
  • Patent number: 5665704
    Abstract: Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: September 9, 1997
    Assignee: Genentech, Inc.
    Inventors: David Lowe, Brian C. Cunningham, David Oare, Robert S. McDowell, John Burnier
  • Patent number: 5580723
    Abstract: The invention provides methods for the systematic analysis of the structure and function of polypeptides by identifying active domains which influence the activity of the polypeptide with a target substance. Such active domains are determined by substituting selected amino acid segments of the polypeptide with an analogous polypeptide segment from an analog to the polypeptide. The analog has a different activity with the target substance as compared to the parent polypeptide. The activities of the segment-substituted polypeptides are compared to the same activity for the parent polypeptide for the target. A comparison of such activities provides an indication of the location of the active domain in the parent polypeptide. The invention also provides methods for identifying the active amino acid residues within the active domain of the parent polypeptide.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: December 3, 1996
    Assignee: Genetech, Inc.
    Inventors: James A. Wells, Brian C. Cunningham
  • Patent number: 5534617
    Abstract: Human growth hormone variants are disclosed wherein the lysine at position 41 and/or the leucine at position 45 of native human growth hormone, numbered from the mature N-terminus of native human growth hormone, has been replaced with another amino acid. Also claimed are combination variants that have a higher binding affinity to the growth hormone receptor than wild-type human growth hormone.
    Type: Grant
    Filed: May 25, 1993
    Date of Patent: July 9, 1996
    Assignee: Genentech, Inc.
    Inventors: Brian C. Cunningham, Henry Lowman, James A. Wells
  • Patent number: 5506107
    Abstract: We have discovered that growth hormones form ternary complexes with their receptors in which site 1 on the hormone first binds to one molecule of receptor and then hormone site 2 then binds to another molecule of receptor, thereby producing a 1:2 complex. We believe this phenomenon is shared by other ligands having similar conformational structure. Assays based on this phenomenon are useful for identifying ligand agonists and antagonists. Sites 1 and 2 are structurally identified to facilitate generation of amino acid sequence variants of ternary complex-forming ligands. Novel variants of growth hormone, prolactin placental lactogen and other related ligands are provided. As a result of our studies with the ternary complex we have determined that selected antibodies to the receptor for these ligands are capable of acting as ligand agonists or antagonists. Novel growth hormones and novel uses for anti-growth hormone receptor antibodies are described.
    Type: Grant
    Filed: September 29, 1993
    Date of Patent: April 9, 1996
    Assignee: Genentech, Inc.
    Inventors: Brian C. Cunningham, Abraham M. DeVos, Michael G. Mulkerrin, Mark Ultsch, James A. Wells
  • Patent number: 4506010
    Abstract: Changes in the optical density and viscosity measurements of a water-soluble cellulose derivative which is enzyme depolymerizable can be used as a method to determine growth of cellulase-producing microorganisms and cellulose degradation. The method is particularly well suited to the measurement of the effect of pesticides on cellulose degradation.
    Type: Grant
    Filed: December 14, 1981
    Date of Patent: March 19, 1985
    Assignee: Stauffer Chemical Company
    Inventors: Nelson Goodman, Brian C. Cunningham